Selected News from Today's FirstWord

EU regulator fines Lundbeck, eight drugmakers 146 million euros over generic Celexa delay

The European Commission on Wednesday fined nine drugmakers a total of 146 million euros ($196 million) for entering deals that delayed the entry of generic versions of Lundbeck's antidepressant Full story

• AMA votes to recognise obesity as a disease - (Ref. Forbes; Chicago Tribune; CTV News; CNN Health; U.S. News & World; Yahoo!Finance; The New York Times; ABC News; PR Newswire)
• Study finds HPV vaccines cut infection rates by half among adolescent girls in US - (Ref. CDC; Breitbart; Bloomberg; The New York Times; ABC News; Chicago Tribune; U.S. News & World; The Guardian; Yahoo!Finance)
• Protalix enters $280-million supply deal with Brazil for Gaucher disease drug Uplyso - (Ref. SmartMoney; StreetInsider; Yahoo!Finance; Haaretz; Globes; GlobeNewswire)
• Teva to disclose individual pay for senior executives, directors - (Ref. SmartMoney; Teva; Bloomberg; Globes)
• AstraZeneca, Bristol-Myers Squibb's Onglyza fails to show heart benefits in study - (Ref. Yahoo!Finance; AstraZeneca; Bristol-Myers Squibb; The Scotsman; SmartMoney; Yahoo!News; FinanzNachrichten)

Also in the News

• Products:
• Cialis,
• dacarbazine,
• ibrutinib,
• metamfetamine,
• NKTR-181,
• Rapaflo,
• safinamide

• Companies:
• Bausch + Lomb,
• Debiopharm,
• GVK Biosciences,
• Life Technologies,
• Novartis,
• Otsuka,
• Teva

• Markets:
• Brazil,
• EU,
• United States

Most Read Stories in the Past Week

• Novartis CEO discusses plans for Diovan patent expiration
• Pfizer records 5-percent rise in second-quarter profit
• Pfizer may introduce OTC version of Lipitor, sources say
• NICE provisionally rejects Novartis' oral MS drug Gilenya
• HHS drops case against Forest CEO